To the Editor:
We read with great interest the article by Trimarchi et al 1 that investigated the impact of refractory pain and hypertension in patients with acute type B aortic dissection. The authors concluded that this subgroup had a higher in-hospital mortality, and this was particularity evident when these patients were managed medically.
Trimarchi et al 1 did not provide the number of patients with refractory hypertension and pain separately, but conducted the analysis by pooling patients with such conditions in a unique intermediate risk group. Even if these 2 conditions may coexist, it has been demonstrated that refractory hypertension and refractory pain are not directly associated. 2, 3 Therefore, this method seems questionable to us. The unreliability of such a combination was supported by the wide range of 95% confidence intervals in odds ratios relative to the intermediate risk group in the multivariate analysis (1.01 to 10.45). It might be more useful to report the association between each condition and mortality separately.
The poorer outcome observed in the intermediate risk group may be more realistically explained by anatomic conditions than by refractory hypertension or pain. In fact, patients with intermediate risk more often had Marfan syndrome (Pϭ0.03) and descending aorta Ͼ6 cm (Pϭ0.02), arch vessel, and abdominal vessel involvement; and less often, they had a complete false lumen thrombosis (Pϭ0.005). All these anatomic aspects may have played a major role in determining the outcomes in this group. 4 On the other hand, patients experiencing refractory hypertension or pain surprisingly received invasive treatment later than completely asymptomatic patients, thus losing the benefit of an early intervention in selected patients.
Finally, the authors did not provide any definition for refractory hypertension or pain. They reported an overall incidence of 18.9% of this condition among 365 patients with uncomplicated acute type B aortic dissection. These data do not agree with those previously reported from the Massachusetts General Hospital Thoracic Aortic Center database, 2,3 in which refractory hypertension and/or refractory pain was a very common phenomenon that was present in 81% of patients with uncomplicated anatomic conditions. In such studies, refractory hypertension was defined as a need for Ն4 adequately dosed antihypertensive agents used simultaneously to achieve a systemic arterial pressure Յ140/80 mm Hg, 3 and recurrent pain was defined as the return of discomfort after relief of the presenting pain. 2 The authors should mention whether they adopted the same definition and comment on any eventual discrepancy.
In conclusion, results reported by Trimarchi et al 1 do not definitely support the need for routinely performing invasive treatment in patients with recurrent pain or hypertension in the absence of clear evidence of anatomic complications.
